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Abstract
Background: Overuse of antibiotics is the main force driving the emergence and dissemination of bacterial resistance in the
community. France consumes more antibiotics and has the highest rate of beta-lactam resistance in Streptococcus
pneumoniae than any other European country. In 2001, the government initiated ‘‘Keep Antibiotics Working’’; the program’s
main component was a campaign entitled ‘‘Les antibiotiques c’est pas automatique’’ (‘‘Antibiotics are not automatic’’)
launched in 2002. We report the evaluation of this campaign by analyzing the evolution of outpatient antibiotic use in
France 2000–2007, according to therapeutic class and geographic and age-group patterns.
Methods and Findings: This evaluation is based on 2000–2007 data, including 453,407,458 individual reimbursement data
records and incidence of flu-like syndromes (FLSs). Data were obtained from the computerized French National Health
Insurance database and provided by the French Sentinel Network. As compared to the preintervention period (2000–2002),
the total number of antibiotic prescriptions per 100 inhabitants, adjusted for FLS frequency during the winter season,
changed by 226.5% (95% confidence interval [CI] 233.5% to 219.6%) over 5 years. The decline occurred in all 22 regions of
France and affected all antibiotic therapeutic classes except quinolones. The greatest decrease, 235.8% (95% CI 248.3% to
223.2%), was observed among young children aged 6–15 years. A significant change of 245% in the relationship between
the incidence of flu-like syndromes and antibiotic prescriptions was observed.
Conclusions: The French national campaign was associated with a marked reduction of unnecessary antibiotic
prescriptions, particularly in children. This study provides a useful method for assessing public-health strategies designed
to reduce antibiotic use.
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The emergence and the dissemination of drug-resistant bacterial
strains make treatment decisions challenging and may be
associated with treatment failures. This phenomenon has become
a major public health issue.
Streptococcus pneumoniae is the most commonly identified bacterial
cause of community-acquired invasive infections and pneumonia
[1,2]. Multidrug-resistant pneumococci (MRP) are now ubiqui-
tous, despite the recent availability and now wide use of 7-valent
pneumococcal conjugate vaccine (7-PCV) in developed countries,
with more infections being caused by nonvaccine serotypes [3].
Very few new antimicrobial drugs are expected to become
available in the near future, and several studies support the notion
that antibiotic consumption is a key driving force in the rate
(number of resistant isolates/total number of isolates) of beta-
lactam–resistant pneumococci [4] and in the dissemination of
MRP [5–7]. Furthermore, there is some evidence that decreasing
antibiotic use can lower MRP rates [8]. For instance, the highest
MRP rates are reported in southern Europe [9], southeastern Asia
[10], and North America [11], where antibiotic consumption is
generally higher than in northern Europe [12]. Thus, many
countries have undertaken public health programs to optimize
antibiotic prescriptions in the community [13].
In the early 2000s, France, a country with nearly 62,000,000
inhabitants and nearly 54,000 general practitioners, faced growing
problems with MRP, with .50% of strains showing decreased
penicillin G susceptibility. France w a sa l s oi d e n t i f i e da st h ec o u n t r y
with the highest antibiotic consumptioninEurope[12] and one ofthe
highest antimicrobial users worldwide. Thus, the French government
initiated a long-term nationwide campaign to reduce antibiotic
overuse and control the dissemination of resistant bacteria in the
community. The national program, named ‘‘Keep Antibiotics
Working,’’ was launched in 2001, targeting both the general public
and health care professionals, to encourage surveillance of antibiotic
use and resistance and to promote better-targeted antibiotic use.
Since 2002, a public service campaign entitled ‘‘Les antibiotiques
c’est pas automatique’’ (‘‘Antibiotics are not automatic’’) is launched
each winter with the primary goal of decreasing prescriptions,
particularly during the viral respiratory infection (VRI) epidemic
season and among children, for whom .40% of the prescriptions are
written [14–16].
In this article we evaluate the effectiveness of these campaigns
by analyzing the evolution of outpatient antibiotic use in France
from 2000 to 2007, for each therapeutic class, as well as by
geographic and age-group patterns. We performed a time-series
analysis and accounted for flu-like syndrome (FLS) variations.
Methods
The Campaign (‘‘Antibiotics Are Not Automatic’’)
In 2002 the French National Health Insurance (NHI) launched
a long-term nationwide campaign in the community. From its
conception, the aim of the campaign was to decrease total
antibiotic use in the community by 25%, targeting predominantly
VRIs in young children. An extensive information dissemination
campaign was developed with the central theme ‘‘Antibiotics are
not automatic.’’ Each winter (October–March) it is relaunched, as
higher levels of infections and prescriptions occur during this
period. A description of the campaign is detailed in Text S1.
Definitions and Data Sources
The NHI program covers all medical care provided by
physicians in private practice, community clinics, and hospitals.
Patients pay health service fees, which are refunded by the NHI.
In France, everyone, even those with low or no income, are
covered by the NHI program. We used anonymous computerized
individual data from two main NHI agencies (General Scheme
and Social Scheme), which cover salaried workers and the self-
employed ($91% of the French population), to access all
antibiotics prescribed, dispensed by outpatient pharmacies, and
reimbursed by NHI from 2000 to 2007 (beginning week 27 [July]
2000, ending week 13 [March] 2007). Each drug approved by the
French Drug Agency is assigned a unique seven-digit code that
enables identification of a particular product and its specific
dosage, package size, formulation, and manufacturer. Each file
contains this drug-related information, prescription date, patient’s
sex, year of birth, and region of residence.
Weekly FLS incidence was provided by the French Sentinel
Network [17] (see http://sentiweb.org/). According to the French
Sentinel Network, FLS is defined as the combination of the following
clinical symptoms: sudden onset fever $39uC, myalgia, and
respiratory symptoms such as dyspnea and/or cough. Demographic
data were obtained from the French National Institute for Statistics
and Economic Studies (INSEE, http://www.insee.fr).
We included the European part of France (henceforth referred to
as France),which accounts for 83% of French territoryand 96% of its
population. For each of France’s 22 administrative regions,
reimbursement data were extrapolated to 100% of the regional
population by dividing the number of prescriptions by the
corresponding region’s NHI coverage rate. The results are presented
as the weekly rate of antibiotic prescriptions per 100 inhabitants.
The study concerns antibiotics for systemic use (anatomical
therapeutic class [ATC] code J01) in the community. Antibiotics
were divided into six categories according to the ATC classifica-
tion: penicillins, cephalosporins, macrolides, quinolones, cyclines,
and ‘‘other.’’
Statistical Analysis
Our analysis describes the crude number of antibiotic
prescriptions and FLS incidence over time, overall, and by region,
antibiotic class, and age group (0–5, 6–15, .15 y). We focused on
the period targeted by the public service campaign (October–
March); more specifically, we examined the truncated series
corresponding to a 26-wk period starting at week 40 of year n and
finishing at week 13 of year n+1. We conducted time-series
analyses to quantitatively evaluate the impact of the successive,
annual campaigns on antibiotic consumption. We used interven-
tion models [18–20] that allowed us to estimate crude and FLS-
adjusted effects of the campaign.
The intervention models were built in two steps. For the first
step, we chose the 2000–2002 period preceding the first campaign,
i.e., starting at week 27 in 2000 and ending at week 40 in 2002, as
the baseline and fitted a model to the series of antibiotic
prescriptions accounting for seasonal variations and underlying
autoregressive and moving average processes. As in other southern
and eastern European countries [21], antibiotic consumption in
France shows marked yearly seasonal fluctuations; therefore we
first estimated a periodic trigonometric function and removed it
from the truncated series so that the residual series was in
stationary mode. We then fitted an autoregressive and moving
average (ARMA) model [22] on the residual series, leaving white
noise residual series.
For the second step, we assumed that observations before and
after the campaign were drawn from the same ARMA model with
changes only in the mean. Following this assumption, we removed
the previously estimated periodic trigonometric function from the
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dummy variables, one for each annual campaign, to the ARMA
model identified in step 1 so that only the mean could change. We
quantified the impact of each campaign as the average relative
change for the period (from winter 2002–2003 to winter 2006–
2007) compared with baseline (2000–2002); that is, the ratio of the
observed change over the expected change predicted from the
model had there been no campaign. The same procedure was
repeated after dividing the population into three age categories
(,6, 6–15, and .15 y) as well as considering data of the summer
period (April–September) and data of the entire year (October–
September).
Finally, we further adjusted the intervention model for the
whole population for FLS incidence. We tested the hypothesis of a
different link between antibiotic consumption and FLS incidence
before and after the start of the 2002 campaign by introducing an
interaction term in the model.
Analyses were performed using SAS version 9.1 (SAS Institute,
http://www.sas.com/). All statistical tests were two-tailed; a p-
value of less than 0.05 was considered significant.
Results
Description of the Data
Between July 2000 and March 2007, a total of 453,407,458
individual antibiotic prescriptions were reimbursed by the NHI; all
files were processed for analysis. Because prescription numbers
were similar for men and women (unpublished data), we combined
their data.
Antibiotic prescriptions and FLS fluctuated seasonally, with
higher incidence rates during winter months (Figure 1). Maximal
values differed from one year to another. The number of antibiotic
prescriptions varied between 585,524 (week 33 of 2006) and
2,196,942 (week 3 of 2002) (amplitude ratio 3.8). FLS peaks varied
between 396 (winter 2002–2003) and 939 (winter 2004–2005) cases
per 100,000 inhabitants (amplitude ratio 2.3). The FLS epidemic
began as early as week 45 (third week of November) in the 2003–
2004 season and as late as week 4 (fourth week of January) in the
2001–2002 season. All epidemics occurred between week 40
(beginning of October) and week 13 (end of March).
The mean number of prescriptions per 100 inhabitants for the
general population was 72.4 for the 2000–2001 and 2001–2002
winters; this figure gradually decreased to 56.6 during the 2006–
2007 season (Table 1).
Variations in antibiotic use were observed among France’s 22
administrative regions. Antibiotic consumption declined in all
regions between 2001–2002 and 2006–2007 (Figure 2). In 2000–
2001, 15/22 regions had .70 prescriptions per 100 inhabitants,
but none exceeded this level in 2006–2007. The most important
reduction was observed in the Centre Region (228.4%). Among
the six administrative regions with the highest average number of
prescriptions per 100 inhabitants in 2001–2002 (Nord 91.8,
Picardie 83.3, Haute Normandie 80.3, Lorraine 78.7, Cham-
pagne-Ardenne 78.7, and Poitou-Charentes 77.3), the decrease in
antibiotic use was among the seven highest, with values of
225.2%, 226.1%, 225.6%, 225.2%, 227.1%, and 227.30%,
respectively. Antibiotic prescription differences among regions
persisted after the campaign but were less dramatic.
Penicillins, cephalosporins, and macrolides were the three most
used antibiotic classes at baseline, with 27.0, 16.3, and 16.4
prescriptions per 100 inhabitants; their use also declined the most
(changes of 225.3%, 224.6%, and 230.1%, respectively) among
all antibiotic classes. Quinolones, which remain a less frequently
prescribed antibiotic class (4.2 prescriptions per 100 inhabitants at
baseline), was the only class whose use increased (+12.8%) (Table 1).
For children ,6 y old, the average number of prescriptions per
100 children declined from 193.3 in 2001–2002 to 128.7 in 2006–
2007. For 2- and 3-y-old children, this figure decreased from ,250
to ,150. A substantial reduction of antibiotic use was also
observed for children 6–15 y old and young adults 26–35 y old
(Figure 3).
Time-Series Analysis
Three factors led us to consider 2 y of preintervention data as
sufficient to correctly estimate modifications after 2002: (1) the
stability of the estimated ARMA model parameters for the 2000–
Figure 1. Antibiotic use and flu-like syndromes in France, from July 2000 to March 2007. Weekly totals of antibiotic prescriptions and FLS
cases per 100 inhabitants plotted against time.
doi:10.1371/journal.pmed.1000084.g001
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Gaussian white noise residuals, and (3) the good fit of the one-step-
ahead forecasts of the interrupted ARMA model with observed
antibiotic prescriptions (Figure 4). Estimations of average relative
change, with corresponding 95% confidence intervals (CIs), are
reported in Table 2. The first campaign yielded immediate
returns, with statistically significant estimated reductions for the
whole population and for inhabitants .15 y old (29.8% [95% CI
214.9% to 24.7%] and –12.5% [95% CI 216.8% to 28.1%],
respectively). The evolution of this change differed according to
age group. Nevertheless, by 2006–2007, the campaign had
achieved significantly fewer antibiotic prescriptions: rates were
227.0% (95% CI 233.5% to 220.5%) versus baseline for the
whole population, 230.1% (95% CI 240.7% to 219.6%) for the
youngest children, 235.8% (95% CI 248.3% to 223.2%) for 6-
to 15-y-olds, and 220.5% (95% CI 225.6% to 215.4%) for those
.15 y (Table 2).
As expected, the FLS incidence rate was significantly associated
with the weekly rate of antibiotic prescription (p,0.0001).
However, a significant decrease of 45% in the linear regression
coefficient between FLS incidence and antibiotic prescriptions was
observed after the first campaign (1.19 before versus 0.66 after,
p=0.006). After controlling for the influence of the FLS incidence
rate, we observed a 226.5% (95% CI 233.5% to 219.6%)
change in winter antibiotic consumption for the total population, a
decrease similar to that obtained without controlling for the FLS
incidence rate. Including four dummy variables in the model for
the April–September period did not show any clear change during
Table 1. Mean number of prescriptions between October and March, per 100 inhabitants (percent change compared to 2000–
2002).
Antibiotic Class 2000–2002 2002–2003 2003–2004 2004–2005 2005–2006 2006–2007
Penicillins 27.0 21.7 (219.6) 21.5 (220.4) 20.7 (223.6) 20.8 (223.2) 20.2 (225.3)
Cephalosporins 16.3 13.6 (217.0) 14.7 (210.2) 14.6 (210.7) 12.5 (223.7) 12.3 (224.6)
Macrolides 16.4 14.2 (213.7) 14.2 (213.8) 13.9 (215.3) 12.4 (224.4) 11.5 (230.1)
Quinolones 4.2 4.3 (3.2) 4.3 (2.8) 4.8 (14.2) 4.6 (8.6) 4.7 (12.8)
Cyclines 3.1 3.1 (1.0) 3.2 (3.7) 3.2 (3.2) 3.1 (1.1) 3.0 (23.7)
Other 5.3 8.1 (55.0) 8.5 (62.0) 7.4 (40.6) 5.1 (23.8) 4.8 (28.0)
All 72.4 65.1 (210.1) 66.4 (28.3) 64.5 (210.8) 58.4 (219.3) 56.6 (221.9)
doi:10.1371/journal.pmed.1000084.t001
Figure 2. Winter antibiotic prescriptions in France by region, from October 2000 to March 2007. The number of October–March
prescriptions is divided by the number of regional inhabitants for the respective year in each of 22 France’s regions: Al (Alsace), Aq (Aquitaine), Auv
(Auvergne), BN (Basse Normandie), Bou (Bourgogne), Br (Bretagne), CA (Champagne-Ardenne), Ce (Centre), Co (Corse), HN (Haute Normandie), Li
(Limousin), Lo (Lorraine), LR (Languedoc-Roussillon), IDF (Ile de France), FC (Franche-Conte ´), MP (Midi-Pyre ´ne ´es), NPDC (Nord-Pas de Calais), PACA
(Provence-Alpes-Cote d’Azur), PDL (Pays de Loire), PC (Poitou-Charente), Pi (Picardie), RA (Rhones Alpes).
doi:10.1371/journal.pmed.1000084.g002
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March prescriptions for each age group for each year is divided by the number of inhabitants of each age group.
doi:10.1371/journal.pmed.1000084.g003
Figure 4. One step ahead forecasts of the interrupted ARMA model and observed antibiotic prescriptions data. October–March
horizontal lines indicate the estimated average level by the interrupted ARMA model (in red) and the observed average level without any campaign
effect (in black) each winter. The percentages listed above the peaks denote the ratio of change.
doi:10.1371/journal.pmed.1000084.g004
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to 25%, but were not significant. In 2006, an estimated decrease
of 28.5% was marginally significant (p=0.08).
Discussion
Between 2002 and 2007, we observed an overall 26.5%
reduction (adjusted for FLS fluctuations) of winter antibiotic
prescriptions in France; the reduction was consistent across all age
groups and all 22 regions, as well as across the most frequently
used therapeutic classes. The initial objective of the ‘‘Keep
Antibiotics Working’’ program to reduce antibiotic use in the
community by 25% was reached in 5 years.
The impact of educational campaigns aimed at decreasing
antibiotic prescriptions by preventing antibiotic misuse at the
population level has rarely been evaluated. In Europe the
European Surveillance of Antimicrobial Consumption (ESAC,
http://www.esac.ua.ac.be) program collects data on antimicrobial
consumption in ambulatory care and hospital settings from 34
European countries’ national surveillance systems and publishes a
yearly report [23]. In the United States, investigations on
antibiotic consumption trends are based on data recorded for a
population sample as provided by the National Ambulatory
Medical Care Survey [24–27]. Other published North American
studies evaluated interventional campaigns but are based on data
from only a few medical practices [28,29], Medicaid [30], or other
medical care providers [31–36]. Few other interventional studies
based on national data are available: Belgium [37], Sweden [38],
and Australia [39]. Prescription data in North America have also
been analyzed in several areas (British Columbia, Wisconsin, and
Minnesota) [40,41].
In the European Union, several countries have initiated
national campaigns to optimize antibiotic use [42]. Our results
are consistent with the recently published article from the ESAC
program; this article similarly reported a reduction of .15% of
antimicrobial drug use for penicillins, cephalosporins, and
macrolides (similarly, no reduction was noted for quinolones)
during the 2000–2004 period [4]. The overall decline we observed
can be compared to those observed in three other national studies
for which comparable data are available: Belgium, Sweden, and
Australia. In Belgium, a significant decrease (after controlling for
FLS variation) was obtained after the first year but not after the
second [37]; a longer follow-up might show a more pronounced
and long-term decrease [43]. In Sweden, a country that had one of
the lowest antibiotic consumption rates in Europe [23], an
intervention was launched in 1995 [44]. This intervention did
not involve a public campaign and was reported as having led to a
220% change in overall antibiotic sales between 1995 and 2004
[38]. The Australian investigation focused mainly on consumer
awareness and physician behavior changes [39].
In France, comprehensive coverage of the population by the
NHI and drug reimbursement for outpatient care offer a unique
opportunity for in-depth analysis of drug use data, in particular use
of antibiotics among outpatients for almost the entire population.
To the best of our knowledge, this is the largest body of data—with
nearly half a billion data entries and the longest time-series of
individual and weekly data on antibiotic prescriptions—to
evaluate antibiotic use in the community ever analyzed.
Our data show that the primary objective of the French national
campaign was largely achieved, with a 30.1% decrease in
antibiotic use in children ,6 y old. This result is very encouraging,
because a substantial proportion of antibiotic prescriptions for
young children are unnecessary because of the viral origins of their
infection [26]. The most important decrease in antibiotic use for
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clear explanation for this change, but it suggests that repeated
campaigns may be necessary to overcome initial resistance by
parents and physicians to reduced antibiotic prescription.
In addition, children aged 6–15 y also had significantly lower
antibiotic use (a 235.8% change over the study period). This change
may be due to the use of rapid tests to diagnose group A streptococci
tonsillitis, which was promoted by the campaign in this age group,
which is at a higher risk of group A streptococci throat infections.
Antibiotic consumption changed by 224.1% among young
adults (26–35 y), who were initially the biggest antibiotic
consumers among adults. Demographic characteristics of this
population suggest that most parents of young children fall within
this age category; as a result, it is likely that young adults have been
specifically affected by the campaign. Finally, prescriptions in the
21–25 y age group remained stable from 2000 to 2007 (as
compared to decreases observed in older and younger age groups).
Two hypotheses may explain this observation. First, 21- to 25-y-
old adults are less likely to live in or interact with collective
institutions (daycares, schools, etc.) or be in close contact with
children than other age groups; as a result, they are less likely to be
exposed to VRIs, which are typically spread by young children.
Second, it may be difficult to further decrease antibiotic use in this
age group, as they already represent the age group with the lowest
antibiotic prescription rate before the campaign.
While crude results did not differ markedly from those adjusted
for FLS fluctuations, accounting for the latter was crucial to the
interpretation of the changes recorded. Indeed, in many countries,
VRIs account for a high share of unnecessary antibiotic
prescriptions. Our intervention model highlighted a significant
weakening of the association between FLS incidence rates and
antibiotic prescriptions after the second yearly campaign. This
observation suggests that the fraction of antibiotics prescribed for
viral illnesses has significantly decreased, which is a highly
encouraging result, as one of the campaign’s main objectives was
to reduce VRI-associated antibiotic overuse. However, the
association between FLS and antibiotic prescriptions persists, at
a low level, even after the campaign.
Several limitations of this study should be noted. First, due to
the quasiexperimental design (i.e., absence of a control group) and
limited preintervention data, a cause–effect relationship between
the campaign ‘‘Antibiotics are not automatic’’ and decreased
antibiotic use cannot be proved. For example, the influence of the
antibiotic campaigns in other geographically proximate European
countries such as Belgium cannot be excluded. Some southern
European countries also conducted campaigns during the 2002–
2007 period (Greece: mass media campaign in 2001–2003; Spain:
mass media campaign since 2006; Portugal: radio campaign in
2004–2007) and observed evolution of outpatient antibiotic use
[23]. Thus, effects of targeted campaigns versus the spontaneous
decrease of antibiotic use should be evaluated in Europe. Very few
new antibiotics have been launched in the past decade; as a result,
the promotion of antibiotic prescription by the pharmaceutical
industry has probably decreased. This might be a confounding
factor for the observed reduction of antibiotic use.
Second, we did not have access to information about the
pathology for which antibiotics had been prescribed. In France, no
information system exists that provides easy access to data linking
drug use to a clinical condition.
Third, we did not account for the introduction of the 7-PCV in our
analysis. The 7-PCV initially received marketing authorization in
France in 2002, specifically for children presenting specific risk
factors. It became widely used only at the end of 2006, once it had
been recommended for all children ,2 y old (unpublished data). It is
thus unlikely that its market introduction could explain much of the
decreased antibiotic use observed over the 5-year investigation
period.
Fourth, FLS surveillance data do not account for other VRIs
such as infections due to respiratory syncytial virus, which
generally occur several weeks before a flu outbreak. It was not
feasible to account for these viral infections, as surveillance data of
these infections are not available in France. As a result, it is likely
that we underestimated the association between community viral
infection and antibiotic prescription.
Fifth, other local initiatives were promoted in France since
2000, such as the campaign ‘‘Antibiotics Only When Necessary’’
promoted in a county in southeastern France (see http://www.
gepie.org/). The added value of such initiatives was not specifically
investigated.
Sixth, some authors have reported that antibiotics may
substantially reduce the risk of pneumonia after chest infection
[45]. Therefore, adverse effects of reduced antibiotic use (e.g.,
increase in certain severe infections) is questionable. We do not
address this question here, which remains to be investigated.
Reasons for reduced antibiotic prescriptions, e.g., fewer
consultations or improved prescribing, were not evaluated here,
the data did not provide the necessary information to address this
question. It has been reported that mass media campaigns play a
role in influencing antimicrobial prescription practice in the UK
[46]. Due to the multifaceted approach and targeting of the
general public and physicians in parallel, the individual effect of
each approach could not be evaluated. We believe that the success
of the intervention was in fact a result of the combined approach,
e.g., face-to-face peer education and widespread public cam-
paigns, allowing both the practitioner not to prescribe and the
patient not to ask for antibiotic therapy.
The results of the present report are highly promising in terms of
bacterial resistance control. A recent European study confirms the
ecological relationship between antibiotic consumption and rate of
MRP at the national level [4]. This study strongly underlines the
responsibility of countries with higher levels of antibiotic use and
recommendsthat they urgently undertakecampaigns devoted tothe
control of MRP, including the promotion of prudent antibiotic use.
In France from 2001 to 2006, a decreasing trend was observed
in the rate of pneumococci resistant to penicillin (47% to 32% of
isolates) and the rate of pneumococci resistant to macrolides (49%
to 36%) in France (see http://www.rivm.nl/earss). Because our
campaign did not target any specific therapeutic class, it may have
prevented interclass switching. Nevertheless, a slight increase of
quinolone prescriptions occurred. Although this was a moderate
increase compared to large decreases recorded for all other classes,
this trends points to the need for careful monitoring of quinolone-
resistant bacteria in the community [47].
Despite the sharp reduction of antibiotic prescriptions observed,
France remains a high user of antibiotics [23]. Nevertheless, the
impact of the decrease in antibiotic use on the prevalence of
infections caused by antimicrobial-susceptible and antimicrobial-
resistant strains mustbe investigated.Future studies should combine
the assessment of 7-PCV vaccination and antibiotic-reduction
policies, and evaluate their respective role in the evolution of S.
pneumoniae invasive infections, according to strain susceptibility.
Supporting Information
Text S1 Description of the public health campaign
‘‘Antibiotics are not automatic’’ between 2002 and 2007.
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Background. In 1928, Alexander Fleming discovered
penicillin, the first antibiotic (a drug that kills bacteria). By
the early 1940s, large amounts of penicillin could be made
and, in the following decades, several other classes of
powerful antibiotics were discovered. For a time, it looked
like bacteria and the diseases that they cause had been
defeated. But bacteria rapidly became resistant to these
wonder drugs and nowadays, antibiotic resistance is a
pressing public-health concern. Almost every type of
disease-causing bacteria has developed resistance to one
or more antibiotic in clinical use, and multidrug-resistant
bacteria are causing outbreaks of potentially fatal diseases in
hospitals and in the community. For example, multidrug-
resistant Streptococcus pneumoniae (multidrug-resistant
pneumococci or MRP) is now very common. S. pneumoniae
colonize the nose and throat (the upper respiratory tract)
and can cause diseases that range from mild ear infections to
life-threatening pneumonia, particularly in young children
and elderly people.
Why Was This Study Done? For years, doctors have been
prescribing (and patients have been demanding) antibiotics
for viral respiratory infections (VRIs) such as colds and flu
even though antibiotics do not cure viral infections. This
overuse of antibiotics has been the main driving force in the
spread of MRP. Thus, the highest rate of S. pneumoniae
antibiotic resistance in Europe occurs in France, which has
one of the highest rates of antibiotic consumption in the
world. In 2001 France initiated ‘‘le plan national pour
pre ´server l’efficacite ´ des antibiotiques’’ to reduce the
inappropriate use of antibiotics, particularly for the
treatment of VRIs among children. The main component of
the program was the ‘‘Antibiotiques c’est pas automatique’’
(‘‘Antibiotics are not automatic’’) campaign, which ran from
2002 to 2007 during the winter months when VRIs mainly
occur. The campaign included an educational campaign for
health care workers, the promotion of rapid tests for
diagnosis of streptococcal infections, and a public
information campaign about VRIs and about antibiotic
resistance. In this study, the researchers evaluate the
campaign by analyzing outpatient antibiotic use
throughout France from 2000 to 2007.
What Did the Researchers Do and Find? The researchers
obtained information about antibiotic prescriptions and
about the occurrence of flu-like illnesses during the study
period from the French National Health Insurance database
and national disease surveillance system, respectively. After
adjusting for variations in the frequency of flu-like illnesses,
compared to the preintervention period (2000–2002), the
number of antibiotic prescriptions per 100 inhabitants
decreased by a quarter over the five winters of the
‘‘Antibiotics are not automatic’’ campaign. The use of all
major antibiotic classes except quinolones decreased in all
22 regions of France. Thus, whereas in 2000, more than 70
prescriptions per 100 inhabitants were issued during the
winter in 15 regions, by 2006/7, no regions exceeded this
prescription rate. The greatest decrease in prescription rate
(a decrease of more than a third by 2006/7) was among
children aged 6–15 years. Finally, although the rates of
antibiotic prescriptions reflected the rates of flu-like illness
throughout the campaign, by 2006/7 this relationship was
much weaker, which suggests that fewer antibiotics were
being prescribed for VRIs.
What Do These Findings Mean? These findings indicate
that the ‘‘Antibiotics are not automatic’’ campaign was
associated with a reduction in antibiotic prescriptions,
particularly in children. Because the whole French
population was exposed to the campaign, these findings
do not prove that the campaign actually caused the
reduction in antibiotic prescriptions. The observed
decrease might have been caused by other initiatives in
France or elsewhere or by the introduction of a S.
pneumoniae vaccine during the study period, for example.
However, an independent survey indicated that fewer
members of the public expected an antibiotic prescription
for a VRI at the end of the campaign than at the start, that
more people knew that antibiotics only kill bacteria, and that
doctors were more confident about not prescribing
antibiotics for VRIs. Thus, campaigns like ‘‘Antibiotics are
not automatic’’ may be a promising way to reduce the
overuse of antibiotics and to slow the spread of antibiotic
resistance until new classes of effective antibiotics are
developed.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/
10.1371/journal.pmed.1000084.
N This study is further discussed in a PLoS Medicine
Perspective by Stephen Harbarth and Benedikt Huttner
N The Bugs and Drugs Web site from the UK National
electronic Library of Infection provides information about
antibiotic resistance and links to other resources
N The US National Institute of Allergy and Infectious Diseases
provides information on antimicrobial drug resistance and
on pneumococcal pneumonia
N The US Centers for Disease Control and Prevention also
have information on antibiotic resistance (in English and
Spanish)
N The European Surveillance of Antimicrobial Consumption
Web site provides information on antibiotic consumption
in European countries
N Les antibiotiques c’est pas automatique provides informa-
tion about the ‘‘Antibiotics are not automatic’’ campaign
(in French)
N Information on the Plan National pour Pre ´server l’efficacite ´
des antibiotiques is also available (in French)
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